Concepts (69)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Migraine Disorders | 9 | 2024 | 64 | 4.570 |
Why?
|
Headache Disorders | 2 | 2022 | 3 | 1.660 |
Why?
|
Headache | 4 | 2024 | 104 | 1.400 |
Why?
|
Biphenyl Compounds | 1 | 2024 | 56 | 0.900 |
Why?
|
Post-Traumatic Headache | 2 | 2022 | 5 | 0.880 |
Why?
|
Tension-Type Headache | 1 | 2022 | 1 | 0.850 |
Why?
|
Headache Disorders, Primary | 1 | 2022 | 1 | 0.810 |
Why?
|
Calcitonin Gene-Related Peptide | 2 | 2020 | 87 | 0.810 |
Why?
|
Neurofibromatosis 1 | 1 | 2022 | 58 | 0.760 |
Why?
|
Life Style | 1 | 2024 | 390 | 0.760 |
Why?
|
Astrocytoma | 1 | 2022 | 102 | 0.750 |
Why?
|
Tuberous Sclerosis | 1 | 2022 | 121 | 0.720 |
Why?
|
Creutzfeldt-Jakob Syndrome | 1 | 2019 | 6 | 0.650 |
Why?
|
Psychotic Disorders | 1 | 2019 | 139 | 0.570 |
Why?
|
Disease Management | 1 | 2020 | 512 | 0.540 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 1231 | 0.540 |
Why?
|
Brain Neoplasms | 1 | 2022 | 1215 | 0.420 |
Why?
|
Pediatrics | 2 | 2018 | 1134 | 0.350 |
Why?
|
Adolescent | 9 | 2024 | 18761 | 0.290 |
Why?
|
Tetrazoles | 1 | 2024 | 63 | 0.220 |
Why?
|
Benzimidazoles | 1 | 2024 | 128 | 0.210 |
Why?
|
Treatment Outcome | 2 | 2017 | 11690 | 0.190 |
Why?
|
Humans | 13 | 2024 | 121122 | 0.190 |
Why?
|
Child | 7 | 2022 | 23984 | 0.160 |
Why?
|
Receptors, Calcitonin Gene-Related Peptide | 1 | 2018 | 20 | 0.160 |
Why?
|
Dihydroergotamine | 1 | 2017 | 10 | 0.150 |
Why?
|
Adult | 4 | 2022 | 28389 | 0.150 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2018 | 71 | 0.140 |
Why?
|
Melatonin | 1 | 2017 | 25 | 0.140 |
Why?
|
Health Surveys | 1 | 2018 | 231 | 0.140 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2017 | 68 | 0.140 |
Why?
|
Venous Thrombosis | 1 | 2017 | 180 | 0.120 |
Why?
|
Follow-Up Studies | 2 | 2020 | 4966 | 0.110 |
Why?
|
Inpatients | 1 | 2017 | 479 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 1005 | 0.100 |
Why?
|
Telemedicine | 1 | 2018 | 418 | 0.100 |
Why?
|
Time Factors | 1 | 2020 | 5976 | 0.090 |
Why?
|
Risk Factors | 1 | 2024 | 9617 | 0.090 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 1055 | 0.080 |
Why?
|
Retrospective Studies | 2 | 2024 | 15593 | 0.080 |
Why?
|
Feasibility Studies | 2 | 2018 | 721 | 0.060 |
Why?
|
Patient Selection | 2 | 2018 | 645 | 0.060 |
Why?
|
Child, Preschool | 2 | 2018 | 13733 | 0.060 |
Why?
|
Pilot Projects | 2 | 2018 | 1355 | 0.050 |
Why?
|
Male | 5 | 2019 | 58941 | 0.050 |
Why?
|
Contraindications, Drug | 1 | 2018 | 2 | 0.040 |
Why?
|
Cluster Headache | 1 | 2018 | 2 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2018 | 100 | 0.040 |
Why?
|
Body Size | 1 | 2018 | 51 | 0.040 |
Why?
|
Prospective Studies | 2 | 2018 | 5858 | 0.040 |
Why?
|
Lidocaine | 1 | 2017 | 48 | 0.040 |
Why?
|
Administration, Intravenous | 1 | 2017 | 142 | 0.030 |
Why?
|
Tertiary Care Centers | 1 | 2017 | 227 | 0.030 |
Why?
|
Catheters, Indwelling | 1 | 2017 | 156 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2018 | 376 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 1674 | 0.030 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2018 | 491 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 1075 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2018 | 478 | 0.030 |
Why?
|
Young Adult | 2 | 2018 | 8645 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2017 | 1389 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2018 | 569 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2017 | 1542 | 0.030 |
Why?
|
Female | 4 | 2018 | 64043 | 0.020 |
Why?
|
Incidence | 1 | 2017 | 2969 | 0.020 |
Why?
|
Pregnancy | 1 | 2018 | 6854 | 0.020 |
Why?
|
Aged | 1 | 2017 | 18432 | 0.010 |
Why?
|
Middle Aged | 1 | 2017 | 25297 | 0.010 |
Why?
|
Animals | 1 | 2018 | 33423 | 0.010 |
Why?
|